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Introduction: Bipolar disorder (BD) is a prevalent, comorbid, and impairing condition. Potential 
predictors of response to pharmacological treatment are object of continuous investigation in 
patients with BD. The present naturalistic study was aimed to assess clinical features and long-
term response to mood stabilizers in a sample of bipolar subjects with different ages at onset.
Methods: The study sample included 108 euthymic patients, diagnosed as affected by BD, 
either type I or II, according to the DSM-IV-TR, who were started on mood stabilizer treatment. 
Patients were followed-up for 24 months and the occurrence of any mood episode collected. 
At the end of the follow-up, patients were divided in 3 subgroups according to the age at onset 
(early-onset 30 years, middle-onset 30–45 years, and late-onset 45 years, respectively) 
and the long-term response to mood stabilizers was compared between them along with other 
clinical features.
Results: The three subgroups showed significant differences in terms of clinical and demographic 
features and, with respect to long-term response to mood stabilizers, the early-onset subgroup 
showed a better outcome in terms of reduction of major depressive episodes during the 24-month 
follow-up compared to the other subgroups (one way ANOVA, F = 3.57, p = 0.032).
Conclusions: Even though further controlled studies are needed to clarify the relationship 
between age at onset and outcome in BD, the present follow-up study suggests clinical 
peculiarities and different patterns of response to mood stabilizers across distinct subgroups of 
patients with BD and different ages at onset.
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Introduction
Bipolar disorder (BD) is a chronic and impairing mental disorder with estimated 
lifetime prevalence of around 2.0% in general population.1,2 Pharmacological treatment 
of bipolar patients is often complex and aimed to symptoms remission and, ultimately, 
to the prevention of recurrences. Over the last two decades, researchers have focused 
their efforts in identifying clinical predictors of treatment response and long-term 
outcome in BD. The aim of the present study was to investigate the long-term response 
to mood stabilizers and to examine the associations between other clinical/demographic 
characteristics in a sample of bipolar patients divided into three subgroups according 
to their ages at onset (AAO).
With regard to potential predictors of treatment response in BD, many variables 
have been investigated. The presence of rapid-cycling course, for example, has been 
associated with worse treatment-response, poorer long-term prognosis, and higher 
suicide risk.3–5
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The role of the duration of untreated illness (DUI) 
as predictor of outcome and long-term course in BD is 
controversial with studies indicating a negative influence in 
relation to outcome for longer treatment delay in initiating 
mood stabilizer therapy6 and other investigation reporting 
no differences in the final outcome of long-term treatments, 
lithium in particular.7–10
Studies investigating the prognostic role of gender in BD 
have shown mixed results. An extensive review assessing 
gender differences in terms of presentation and course in 
BD indicated that there was no evidence of gender influence 
on treatment response to mood stabilizers.11 A previous 
retrospective three-year study conducted with 131 bipolar 
patients showed that AAO and number of affective episodes 
of any polarity did not differ across genders.12 A more recent 
retrospective study conducted with 211 bipolar patients 
concluded that men and women were different in terms of 
episode polarity at onset as well as comorbidity patterns, with 
men reporting more frequently mania at the onset of bipolar 
I disorder and also showing higher rates of comorbid alcohol 
and cannabis abuse/dependence.13
With regard to the relationship between AAO and severity 
of clinical features in BD, a recent study reported that early 
AAO was associated with more severe clinical features but 
delayed treatment-seeking.14 A previous large retrospective 
study reported that early (13–18 years) and very early onset 
(13 years) bipolar patients showed higher rates of comorbid 
anxiety disorders and substance abuse, more recurrences, 
shorter periods of euthymia as well as more suicide attempts 
and violent behaviors.15 Furthermore, recent reports suggest 
that late onset BD would be more frequently associated 
with organic brain diseases,16 supporting the hypothesis that 
late onset BD may share some symptom domains with the 
early onset subtype, but have potential different etiology. 
Nevertheless, there is no uniform consensus in defining 
specific thresholds in relation to AAO. On one hand, a 
recent study investigating cognitive impairment in elderly 
bipolar patients defined the onset of BD prior to the age of 
40 years as early-onset.17 Another recent study identifying 
factors contributing to relapse and hospitalization in elderly 
bipolar patients established an AAO cut-off between early 
and late onset BD at age 45.18 On the other hand, threshold 
values for early onset in BD have been repeatedly indicated 
prior to the age of 18 years15 and it is not clear how to con-
sider BD patients between 30 and 40 years with respect to 
AAO. As a matter of fact, Leboyer and colleagues supported 
the existence of three bipolar subgroups based on AAO: 
early (17.4 ± 2.3 years), intermediate (25.1 ± 6.2 years), 
and late-onset (40.4 ± 11.3 years)19 following previous 
investigation in the field.20,21 The authors, however, concluded 
that accurate AAO thresholds to define valid subgroups of 
patients with BD are still an object of debate.
In order to investigate the relationship between long-term 
response to mood stabilizers and AAO in a sample of bipolar 
patients we conducted the present naturalistic study that 
explored this relationship not only in early- and late-onset 
patients but also in intermediate-onset bipolar subjects. 
In addition, associations between other clinical/demographic 
characteristics and long-term response in these sub-groups 
of patients were investigated.
Subjects and methods
subjects
The study sample included initially 137 consecutive euthymic 
drug-free patients (63 males and 74 females) diagnosed as 
affected by BD, either type I or II, according to the Diagnostic 
and Statistical Manual for Mental Disorders, 4th edition, 
text-revision criteria (DSM-IV-TR).22 Euthymia was defined 
as the absence of any major mood episode (depressive, manic/
hypomanic, or mixed) for at least two months.
Diagnoses were made through the administration of a 
semi-structured clinical interview for DSM-Axis I Disorders 
(SCID).23 Before starting the pharmacological treatment with 
mood stabilizers and entering the 24-month follow-up, the 
following demographic (gender and age) and clinical variables 
(family history for mood disorders, age at onset, polarity of 
the first episode, type of BD, age at the first pharmacologi-
cal treatment, duration of untreated illness (DUI), duration 
of illness, comorbidity with other psychiatric disorders, and 
presence of rapid cycling course) were collected.
Exclusion criteria included comorbid organic disorders, 
mental retardation, personality disorders severe enough 
to interfere with study participation (assessed through the 
SCID II), and lack of compliance. If a comorbid disorder was 
present, BD had to be the primary disorder, ie, it caused the 
most significant distress and dysfunction and provided the 
primary motivation to seek treatment.
All patients were assessed, interviewed, treated and 
followed-up at the Mood Disorders Outpatient Clinic within 
the University Department of Psychiatry of Milan and had 
given written informed consent to participate into the study 
after receiving a full explanation of the study protocol.
Methods
After the baseline visit, patients were started on mood-stabilizer 
treatment, entering a 24-month follow-up with monthly 
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control visits. Mood-stabilizer treatment included the 
following psychotropic compounds: Lithium, anticon-
vulsants (ie, valproate and carbamazepine) and atypical 
antipsychotics (ie, quetiapine, olanzapine, and risperidone). 
These compounds were chosen by treating psychiatrists on 
the basis of their clinical evaluations. Each compound had to 
be administered at standard dosages according to currently 
available guidelines,24 and within therapeutic plasma levels 
for lithium and valproate (0.5–1.5 mEq/l and 50–150 µg/ml, 
respectively). Concomitant pharmacological treatment with 
benzodiazepines as prohypnotic agents was allowed whereas 
antidepressant treatment, when present, had to be maintained 
at fixed dosages for all the duration of the follow-up.
The occurrence of any mood episode during the follow-up 
period represented the main outcome measure for assessing 
long-term response. In fact, from the beginning of the study 
and throughout the 24-month follow-up period, patients were 
assessed monthly by trained psychiatrists who administered 
the 21-item Hamilton Depression Rating Scale (HAMD–21)25 
and the Young Mania Rating Scale (YMRS)26 in order to 
identify or to exclude the recurrence of any major mood 
episode. Depressive recurrences were diagnosed through the 
SCID and on the basis of a HAMD-21 total score 18 for 
at least two weeks. Manic and hypomanic recurrences were 
diagnosed through the SCID and on the basis of a YMRS total 
score 20 or YMRS total score 10 and  20 for at least 
one week, respectively. Mixed recurrences were diagnosed 
through the SCID and with a HAMD-21 total score 18 and 
YMRS total score 20 for at least one week. Patients were 
considered euthymic if their HAMD-21 total score was 8 
and their YMRS total score was 10.
For the purpose of the study, at the end of follow-up, 
patients were divided into three subgroups according to the 
AAO: an early onset subgroup (age at onset 30 years); 
a middle onset subgroup (age at onset 30–45 years); 
and a late onset subgroup (age at onset 45 years). Such 
a division was performed taking into account previous 
investigation in the field.19–21 AAO was collected during 
the clinical interview (SCID) by trained psychiatrists (BD, 
MB, RR, SP, RB) with established inter-rater reliability and 
controlled with available relatives. In addition, a further 
control with previous medical/psychiatric records was 
performed for the majority of patients.
Descriptive analyses of demographic and clinical vari-
ables were performed on the total sample and on the three 
subgroups. Long-term response to mood stabilizer treatment 
was compared between the three subgroups of patients 
using one way analysis of variances (ANOVAs), whereas 
dichotomous clinical variables were analyzed with chi-square 
tests. For all the analyses, the level of statistical significance 
was set at 0.05. All the statistical analyses were performed 
using the SPSS for Windows software (version 15.0; SPSS 
Inc., Chicago, IL).
Results
One hundred and eight  patients (43 males and 
65 females) completed the 24-month follow-up. Clinical 
and demographic features of the study sample are reported 
in Table 1. Twenty-nine patients (20 males and nine females) 
did not complete the follow-up for different reasons (nine 
subjects missed two consecutive visits and were excluded 
from the study, nine subjects withdrew from the study due 
to side effects, six patients needed a major change in the 
pharmacological regimen, eg, the augmentation of an anti-
depressant or a second mood stabilizer, and five subjects 
were not compliant to the prescribed therapy) and were not 
included in the final analysis. Nevertheless, drop-outs were 
homogeneous across the three subgroups of patients.
Mean AAOs were respectively 23.39 years (± 4.78) in the 
early-onset subgroup, 37.13 years (± 4.15) in the middle onset 
subgroup, and 53.42 years (± 5.79) in the late-onset subgroup.
In terms of clinical and demographic characteristics, the 
three subgroups were different with respect to the type of 
mood stabilizer prescribed, with a prevalence of atypical 
antipsychotics in the late-onset subgroup and lithium/
valproate in the early-onset subgroup (χ2 = 34.74, df = 14; 
p = 0.001). The duration of illness was significantly higher 
in the early-onset subgroup compared to the late-onset sub-
group (F = 8.43; p  0.0001; Bonferroni, p  0.0001) as 
well as the DUI (F = 3.59; p = 0.031; Bonferroni, p = 0.026). 
The age at the first pharmacological treatment was higher 
in the late-onset subgroup compared to the other subgroups 
(F = 102.10; p  0.0001; Bonferroni, p  0.0001). Base-
line comorbidity with other psychiatric disorders showed 
a higher prevalence of substance abuse in the early-onset 
subgroup compared to the other subgroups (χ2 = 28.28, 
df = 16; p = 0.022). There were no differences with respect 
to gender (χ2 = 1.58, df = 2; p = 0.516), diagnostic subtype 
(χ2 = 0.09, df = 2; p = 0.967), development of rapid cycling 
course (χ2 = 0.72, df = 2; p = 0.771), type of the first episode 
(χ2 = 3.49, df = 2; p = 0.17), and family history for psychiatric 
disorders (χ2 = 2.71, df = 6; p = 0.87).
With respect to long-term response, mood stabilizers 
showed to be more effective in preventing major depressive 
episodes in the early-onset subgroup compared to the other 
subgroups (F = 3.57, p = 0.032; Bonferroni, p = 0.014). 
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Table 1 Demographic and clinical features of the total sample and of the three subgroups divided according to the age at onset
N Total sample Early onset Middle onset Late onset
108 51 38 19
Gender Male 43 (39.8) 19 (37.3) 14 (36.8) 10 (52.6)
Female 65 (60.2) 32 (62.7) 24 (63.2) 9 (47.4)
Diagnosis Bipolar I 39 (36.1) 19 (37.3) 13 (34.2) 7 (36.8)
Bipolar II 69 (63.9) 32 (62.7) 25 (65.8) 12 (63.2)
Type of first episode Depressive 80 (74.0) 34 (66.7) 32 (84.2) 14 (73.7)
Manic/hypomanic 28 (26.0) 17 (33.3) 6 (15.8) 5 (26.3)
Family history None 49 (45.4) 22 (43.1) 18 (47.4) 9 (47.4)
Affective disorders 48 (44.4) 23 (45.1) 17 (44.7) 8 (42.0)
Schizophrenia 4 (3.7) 1 (2.0) 2 (5.3) 1 (5.3)
Anxiety disorders 7 (6.5) 5 (9.8) 1 (2.6) 1 (5.3)
Comorbidity°  
(Lifetime)
None 65 (60.1) 27 (52.9) 22 (57.9) 16 (84.2)
Substance abuse 11 (10.2) 10 (19.6) 0 (0.0) 1 (5.3)
Personality disorders 2 (1.9) 1 (2.0) 1 (2.6) 0 (0.0)
Panic disorder 15 (13.9) 7 (13.7) 7 (18.4) 1 (5.3)
General anxiety disorder 5 (4.6) 1 (2.0) 4 (10.5) 0 (0.0)
Obsessive-compulsive disorder 4 (3.7) 4 (7.8) 0 (0.0) 0 (0.0)
Eating disorders 3 (2.8) 1 (2.0) 2 (5.3) 0 (0.0)
Somatoform disorders 3 (2.8) 0 (0.0) 2 (5.3) 1 (5.3)
Rapid cycling Yes 16 (14.8) 7 (13.7) 7 (18.4) 2 (14.8)
No 92 (85.2) 44 (86.3) 31 (81.6) 17 (85.2)
Mood stabilizers∞
Atypical antipsychotics 20 (18.5) 4 (7.8) 7 (18.4) 9 (47.4)
Lithium 43 (39.8) 28 (54.9) 12 (31.6) 3 (15.8)
Anticonvulsants 45 (41.7) 19 (37.3) 19 (50.0) 7 (36.8)
Age* 51.06 (± 12.59) 44.47 (± 12.01) 53.32 (± 9.37) 64.26 (± 6.61)
Age of the first pharmacological treatment** 36.83 (± 11.93) 28.08 (± 8.19) 39.84 (± 5.69) 54.32 (± 5.85)
Duration of untreated illness (DUI)◊ years 10.04 (± 9.79) 11.88 (± 11.04) 10.08 (± 9.03) 5.00 (± 5.25)
Duration of illness years 17.31 (± 10.03) 20.75 (± 10.91) 15.97 (± 8.69) 10.74 (± 5.45)
Number of depressive episodes after 24 months  
of treatment
0.99 (± 1.45) 0.61 (± 0.90) 1.37 (± 2.06) 1.26 (± 0.87)
Number of manic/hypomanic episodes after 
24 months of treatment
0.41 (± 1.33) 0.27 (± 0.72) 0.68 (± 2.06) 0.21 (± 0.42)
Number of mixed episodes after 24 months  
of treatment
0.29 (± 0.66) 0.29 (± 0.73) 0.37 (± 0.68) 0.11 (± 0.32)
Notes: standard deviations and percentages are sorted into brackets and refer to single group.
Statistics: °χ2 = 28.28, df = 16, p = 0.022; ∞χ2 = 34.74, df = 14, p = 0.001; *F = 26.70, p  0.0001; **F = 102.10, p  0.0001; ◊F = 3.59, p = 0.03; F = 8.43, p  0.0001; 
F = 3.57, p = 0.03.
No differences were found among the three subgroups with 
regard to mood stabilizer response in terms of prevention of 
manic/hypomanic (F = 1.29; p = 0.28) and mixed episodes 
(F = 1.02; p = 0.363).
Discussion
Demographic and clinical features of study sample are 
consistent with literature data, given a higher prevalence of 
early-onset subjects13 and a significant rate of rapid-cycling 
patients, approximately the 15% of the sample.27 It is 
noteworthy to highlight a DUI of approximately 10 years in 
the study sample which is consistent with published data in 
the field.6 In addition, as in many other studies with bipolar 
patients, a frequent family history of affective disorders28 and 
a frequent comorbidity with panic disorder and substance 
abuse6,29 were found within the study sample.
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With respect to clinical differences among the three 
subgroups divided on the basis of the AAO, early-onset 
patients showed more frequently comorbid substance abuse 
and obsessive compulsive disorder, factors that have been 
associated with poor prognosis.30,31
The main finding of the present study is that mood 
stabilizer treatment seemed to be more effective in preventing 
depressive episodes in early-onset bipolar patients compared 
to middle- and late-onset subjects. This aspect, along with 
a longer DUI in this subgroup of patients, underscores the 
importance of early diagnosis and treatment in relation to 
prognosis and treatment response in these patients. In fact, 
it may be speculated that early-onset bipolar subjects, 
even though characterized by more severe clinical features 
(eg, more frequent comorbidity with substance abuse), 
delayed treatment-seeking,14 and longer DUI, may nonethe-
less show a favorable response to mood stabilizers once these 
compounds are initiated compared to late-onset patients. On 
the other hand, with regard to the prevention of manic/hypo-
manic recurrences, mood stabilizers were equally effective 
across the three subgroups of patients.
Another original indication from the present study in 
terms of long-term response to mood stabilizers according 
to different ages at onset is that middle-onset subjects were 
more similar to late-onset ones, supporting the hypothesis 
that early- and middle-/late-onset BDs might be considered 
distinct subtypes. Of note, a recent epidemiological study 
concluded that AAO reflects underlying genetic heteroge-
neity in BD and, thus, AAO might conceivably be used to 
identify more homogeneous groups of families with BD, 
and thereby facilitate the mapping of illness susceptibility 
genes.32 Genetic investigation would support this hypothesis 
and a recent study showed that the polymorphism Val66Met 
for the gene of brain-derived neurotrophic factor (BDNF) 
would be specifically associated with early AAO in patients 
with BD.33
Further studies with larger samples and longer follow-up 
observation are warranted to confirm present findings which 
are limited by the relatively small sample size and the open 
design. In addition, it should be taken into account that 
differences in treatment-response across different subgroups 
of bipolar patients may have been influenced by the dif-
ferent types of mood stabilizers used given that long-term 
monotherapies such as lithium, anticonvulsants, or atypical 
antipsychotics may have different impact according to 
patients’ clinical profile.34 In this perspective, in fact, 
significant differences regarding the type of mood stabilizer 
prescribed across the three subgroups, with a prevalence 
of atypical antipsychotics in the late-onset subgroup 
and lithium/valproate in the early-onset subgroup, were 
found. The more frequent use of atypical antipsychotics 
in the late-onset subgroup may be read in light of a more 
favorable pharmacodynamic profile and tolerability for these 
agents compared to classical mood stabilizers.35 On the other 
hand, lithium was the most frequently used mood stabilizer in 
the early-onset subgroup, as reported in another retrospective 
study involving 139 early-onset bipolar subjects.36 A poten-
tial explanation of this finding may be that clinicians would 
prescribe lithium for early-onset patients in light of a possible 
better tolerability and greater efficacy of this compound in 
the first phases of BD,37 even though this hypothesis has been 
questioned in recent studies.38,39 Finally, even though the 
collection of AAO was established with the SCID by trained 
psychiatrists and always controlled with additional fonts, 
the possibility of recall bias, particularly for older patients, 
cannot be completely ruled out.
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